2015 제56차 대한혈액학회 춘계학술대회 · 2015. 10. 2. · 3 The 56th Spring Meeting of the Korean Society of Hematology 존경하는 대한혈액학회 회원 여러분!

일 시• 2015년 5월 29일(금) - 30일(토)

장 소•그랜드힐튼호텔(서울 홍은동)

2015 제56차 대한혈액학회

춘계학술대회

3

The 56th Spring Meeting of the Korean Society of Hematology

존경하는 대한혈액학회 회원 여러분!

제56차 대한혈액학회 춘계학술대회가 2015년 5월 29일부터 30일까지 양일간 서울

그랜드힐튼 호텔에서 개최됩니다. 이번 춘계학술대회는 혈액학 분야의 국내외 석학을

모시고, 혈액질환의 진단과 치료, 연구에 관한 최신지견을 함께 나누고자 알찬 프로그램을

준비하였습니다.

Plenary session에서는 혈액학 분야의 최고 권위자중 한분이신 Dr. Wing Leung을

초청하여 “Recent advances in mismatched related transplantation and cellular

therapy”이란 제목으로 최신지견을 듣기로 하였으며, 국내외 혈액학 분야의 여러 석학들이

함께 하여 심도 있는 학술의 장을 열 예정입니다. 특히, 올해에는 중계연구의 활성화를

위하여 대한면역학회와 함께 하는 scient i f ic session을 마련하여, 기초의학자들과

임상의학자들이 교류하며 학문적 성과를 극대화할 수 있는 자리를 마련해 보고자

했습니다. 또한 이번 춘계학술대회에는 회원들의 학문적 열정을 반영해 토요일 오후를

이용하여 대한혈액학회의 자랑인 산하 연구회들의 연구성과와 관련 최신지견을 나누는

시간을 마련하였습니다. 향후 춘계와 추계로 나누어 13개 연구회의 session을 마련할

예정이며 이번 춘계학술대회에서는 다발성골수종연구회, 성인급성림프모구백혈병연구회,

혈우병연구회, 급성골수성백혈병/골수형성이상증후군연구회, 정맥혈전증연구회,

조직구증식증연구회 등 6개 연구에서 유익한 세션을 준비하였습니다. 많은 관심과 참석을

부탁드립니다. 이번 춘계학술대회에서는 각 회원들께서 그동안 진행해 오셨던 연구 성과를

보다 활발히 나눌 수 있는 시간도 마련하였습니다. 구연발표뿐 아니라 포스터 발표시에도

우수포스터 발표시간을 준비하여 발표자와 회원간에 활발한 토론을 통해 한층 깊이있는

학술대회가 될 수 있도록 준비하였습니다.

회원 여러분들의 많은 관심과 적극적인 참여를 통해 대한혈액학회가 더욱 발전할 수 있는

시간이 될 수 있도록 함께하여 주시길 바랍니다.

춘계학술대회장에서 뵙겠습니다.

2015년 4월

대한혈액학회 회 장 서 종 진

이사장 김 선 희

초대의 글

대한혈액학회 회장 서 종 진

대한혈약학회 이사장 김 선 희

Contents 03 초대의 글 04 춘계학술대회 프로그램 07 춘계학술대회 등록안내 및 임원명단

08 춘계학술대회 연자 소개

25 대한혈액학회 학술위원회 소개 26 Convention Hall Information

5대한혈액학회 춘계학술대회 | 4

제56차 대한혈액학회 춘계학술대회 The 56th Spring Meeting of the Korean Society of Hematology

Program 전체일정표 | May 29th (Friday) Program 전체일정표 | May 30th (Saturday)

Room A Room B Room C08:20 Registration

09:00 Opening Remark

09:10-10:30

Education Session I: Consultative Hematology

Hematologic problems in surgical patients: bleeding Won Sik Lee (Inje Univ.)Hematologic problems in surgical patients: thrombosis Ho-Young Yhim (Chonbuk National Univ.)Consultative hematology: hematologic aspects of pregnancy Yu Ri Kim (Yonsei Univ.)Hematologic consultation from NICU/PICU Hoi Soo Yoon (Kyung Hee Univ.)

10:30-11:20Plenary Session Recent advances in mismatched related transplantation and cellular therapy Wing Leung (St. Jude Children’s Research Hospital, USA)

11:20-12:40Luncheon Symposium and Working Party Reports Changing paradigm of early antifungal treatment for hematologic patients in the era of anti-mold prophylaxis Werner J. Heinz (Wuerzburg Univ. Medical Center, Germany)

12:40-13:40 Poster Rounding

13:40-15:00

Scientific Session I: Basic Science Scientific Session II : Thrombotic Disorders Education Session II: AML/MDS

Role of NK cell in CML therapy Kyung-Mi Lee (Korea Univ.)

Management of VTE in the era of DOAC Doyeun Oh (CHA Univ.)

Optimal treatment approaches for elderly AML Chul Won Choi (Korea Univ.)

Harnessing regulatory T cells for control of immune response in pig to nonhuman primates pancreatic islet transplantation model Chung-Gyu Park (Seoul National Univ.)

DOACs and thrombophilia testing: facts and artifacts Seongsoo Jang (Univ. of Ulsan)

Optimal treatment approach for acute promyelocytic leukemia Yang Soo Kim (Kosin Univ.)

Targeting immune checkpoints can be a new immunotherapy approach for multiple myeloma Inhak Choi (Inje Univ.)

Management of major bleeding with the old and new anticoagulants Kyoung Ha Kim (Soonchunhyang Univ.)

Optimal treatment approaches for AML in children, adolescents, and young adults Bin Cho (The Catholic Univ. of Korea)

15:00-15:30 Coffee Break

15:30-16:30 Oral Presentation I Oral Presentation II Oral Presentation III

16:30-18:00 Oral Presentation IV Oral Presentation V Oral Presentation VI

18:00 Welcome Reception (Grand Ballroom, Hotel 2F)

Room A Room B Room C08:10-09:40 Oral Presentation VII Oral Presentation VIII Oral Presentation IX

09:40-11:00

Scientific Session III: Immunology Scientific Session IV: Lymphoma Education Session III: BM failure

Immunophenotypic aberrations in hemophagocytic lymphohistiocytosis Taizo Wada (Kanazawa Univ., Japan)

Lymphoma genesis of NK/T cell lymphoma YoungHyeh Ko (Sungkyunkwan Univ.)

Bone marrow failure and the telomeropathies Eul-Ju Seo (Univ.of Ulsan)

Current strategy for the management of ENKL Ritsuro Suzuki Lee (Shimane Univ. Cancer Center, Japan)

Current insights into Fanconi anemia Hee Jo Baek (Chonnam National Univ.)

Immunological background of immune checkpoint and its modulation in cancer Eui-Cheol Shin (KAIST)

Treatment guidelines of aplastic anemia: current guidelines and expanding donor possibilities Yeung-Chul Mun (Ewha Womans Univ.)

Future directions of management of ENKL Won Seog Kim (Sungkyunkwan Univ.)

Current issues in the treatment of paroxysmal nocturnal hemoglobinuria Deog-Yeon Jo (Chungnam National Univ.)


11:30-12:10Special Lecture Impact of recent genetic discoveries on MPN management Antonio Almeida (Instituto Português de Oncologia de Lisboa, Portugal)

12:10-13:30Luncheon Symposium and Awards Treatment of transplant eligible myeloma patients Wee Joo Chng (National Univ. Cancer Institute, Singapore)

7

제56차 대한혈액학회 춘계학술대회 The 56th Spring Meeting of the Korean Society of Hematology

대한혈액학회 춘계학술대회 | 6

KSH등록안내

일 시 : 2015년 5월 29일(금) ~ 30일(토)

장 소 : 그랜드힐튼호텔(서울 홍은동)

초록접수 : 2015년 03월 09일(월) ~ 2015년 04월 27일(월)

(*초록은 반드시 영문으로 작성하여 주시기 바랍니다.)

사전등록 : 2015년 03월 09일(월) ~ 2015년 05월 15일(금)

등 록 비 : 사전등록 - 전문의 ￦50,000 / 전공의, 간호사 및 기타 ￦20,000

현장등록 - 전문의 ￦70,000 / 전공의, 간호사 및 기타 ￦30,000

KSH대한혈액학회임원명 단

직 위 성 명 소 속

회 장 서종진 울산의대 서울아산병원 소아청소년과

감 사 오도연 차의과학대 분당차병원 내과

권기영 계명의대 계명대학교병원 내과

이 사 장 김선희 성균관의대 삼성서울병원 진단검사의학과

총무이사 김형준 전남의대 화순전남대학교병원 내과

부 총 무 김진석 연세의대 세브란스병원 내과

학술이사 이제환 울산의대 서울아산병원 내과

학술이사(연구회) 손상균 경북의대 경북대학교병원 내과

재무이사 조 빈 가톨릭의대 서울성모병원 소아청소년과

편집이사 권석운 울산의대 서울아산병원 진단검사의학과

보험이사 정철원 성균관의대 삼성서울병원 내과

법제이사 민창기 가톨릭의대 서울성모병원 내과

간행홍보이사 이우인 경희의대 경희대학교병원 진단검사의학과

정보/홈페이지이사 채석래 동국의대 일산병원 진단검사의학과

국제협력이사 김석진 성균관의대 삼성서울병원 내과

정책기획이사 강형진 서울의대 서울대학교병원 소아청소년과

교육/학술자료관리이사 박현진 국립암센터 소아암센터

특임이사(교과서) 박찬정 울산의대 서울아산병원 진단검사의학과

특임이사(회원관리) 김인호 서울의대 서울대학교병원 내과

특임이사(연구기획) 김병수 고려의대 안암병원 내과

지역이사(대구.경북) 최은진 대구가톨릭의대 대구가톨릭병원 소아청소년과

지역이사(경기.인천) 박성규 순천향의대 부천병원 내과

지역이사(호남) 신명근 전남의대 화순전남대학교병원 진단검사의학과

지역이사(부산.울산,경남) 주영돈 인제의대 해운대백병원 내과

Room A Room B Room C

13:30-15:00

Working Party I: Multiple Myeloma Working Party II: Adult Ph-negative ALL Working Party III: Hemophilia

Diagnosis and prognostic factors of multiple myeloma Yoon Hwan Chang (Korea Cancer Center Hospital)

Current strategies and refinement of risk classification: focusing on clinical factors Ho-Jin Shin (Pusan National Univ.)

Advances in monitoring techniques in hemophilia Eun Jin Choi (Catholic Univ. of Daegu)

Recent advances in the treatment of newly diagnosed multiple myeloma Jin Seok Kim (Yonsei Univ.)

Approaches to detect new genetic subtypes Jung Sook Ha (Keimyung Univ.)

Optimal maintenance therapy for the management of hemophilia Kiyoung Yoo (Korea Hemophilia Foundation)

An update for the treatment of relapsed or refractory multiple myeloma HyeonSeok Eom (National Cancer Center)

Recent advances to detect MRD in acute lymphoblastic leukemia Myungshin Kim (The Catholic Univ. of Korea)

Pain management in bleeding disorders: comparison with other diseases Ji Yoon Kim (Kyungpook National Univ.)


15:20-16:50 Working Party IV: AML/MDS Working Party V: VTE Working Party VI: Histiocytosis

15:20-16:50

Clinical implications of epigenetic regulator gene mutation in AML/MDS Seung Hwan Oh (Inje Univ.)

Results of Korean TTP/HUS registry Doyeun Oh (CHA Univ.)

Current status of a nationwide, multicenter, prospective registry of LCH in Korea Kyung-Nam Koh (Univ. of Ulsan)

Combination therapy including HMA for high risk MDS/AML Silvia Park (Sungkyunkwan Univ.)

Results of prospective study for VTE in medically-ill hospitalized elderly patients Jeong-Ok Lee (Seoul National Univ.)

Genomics of LCH and its clinical implications Jong Jin Seo (Univ. of Ulsan)Study proposal I

Ho-Young Yhim (Chonbuk National Univ.)

Therapeutic challenges for pediatric relapsed or refractory AML Hyery Kim (Chung-Ang Univ.)

Interim report about the efficacy and safety of rivaroxaban in patients with cancer-associated VTE Ho-Young Yhim (Chonbuk National Univ.)

Recent advances in the treatment of HLH Jae Min Lee (Yeungnam Univ.)

Adjunctive targeted therapies combined with reduced intensity conditioning allografts Junshik Hong (Gachon Univ.)

Incidence of thrombosis after L-asparaginase in Korean patients Ji Hyun Lee (Dong-A Univ.)

Clinical spectrum and treatment of macrophage activation syndrome Soo Jeong Kim (Yonsei Univ.)Study proposal II

Kyoung Ha Kim (Soonchunhyang Univ.)

16:50-17:00 Closing Remarks

Program 전체일정표 | May 30th (Saturday)

대한혈액학회 춘계학술대회 | 8 9

5월 29일(금) 09:10 - 10:30 5월 29일(금) 09:10 - 10:30

5월 29일(금) 09:10 - 10:30 5월 29일(금) 10:30 - 11:20

5월 29일(금) 09:10 - 10:30 5월 29일(금) 11:20 - 12:40

Surgical patients often present unique challenges to the consulting hematologist. They may develop unexpected bleeding, which can be potentially life-threatening. This talk reviews the preoperative evaluation of bleeding risk, the management of the patients with hemostatic abnormalities and management of bleeding in surgical patients.

Pediatric hematologists-oncologists in the Korea spend the majority of their time treating malignancies and see patients with nonmalignant hematologic disorders on a less frequent basis. The questions asked are frequently challenging and require proficiency of a broad knowledge base. This talk included most common questions asked from NICU/PICU. Important nonmalignant hematologic problems such as anemia, thrombocytopenia, pancytopenia and bleeding disorder will be described.

Surgical patients often present unique challenges to the consulting hematologist. They may develop unexpected bleeding, which can be potentially life-threatening. This talk reviews the preoperative evaluation of bleeding risk, the management of the patients with hemostatic abnormalities and management of bleeding in surgical patients.

Allogeneic hematopoietic cell transplantation is an established treatment for high-risk hematologic malignancies. Haploidentical donor is readily available but the procedure is complex and may not be successful. Relapse, infection, transplant-related mortality, and late organ toxicity are some problems commonly encountered after transplantation. In this presentation, Prof. Leung will discuss these adverse events and describe novel immune approaches to overcome these barriers. The goal is to improve the efficacy and to reduce the toxicity of mismatched related transplantations to the degree that patient outcomes will be equivalent or superior to those of conventional matched donor transplantations. Clinical implications and practical approaches will be discussed.

Normal pregnancy involves many changes in maternal physiology including alterations in hematologic parameters. There are many problems such as anemia, thrombocytopenia, thrombosis and cancers. Hematologist frequently encountered the hematologic problem of pregnancy. Although we experienced many patients in clinical practice, there is little chance to study these problems. In this talk, I will review and present the hematologic problems of pregnancy.

Fungal infections remain are a life threatening complication in hematological patients. Especially patients with prolonged periods of neutropenia and recipients of allogeneic stem cell transplantation have an increased risk to develop mold but also yeast infections. New therapeutic options and treatment strategies have been established within the last years. The appropriate choice of the antifungal compound, the route of application and time point of initiation may depend on several clinical factors. This talk will discuss different options to prevent or to treat early fungal infections in hematological patients.

Hematologic problems in surgical patients: bleeding

Hematologic consultation from NICU/PICU

Hematologic problems in surgical patients: thrombosis Recent advances in mismatched related transplantation and cellular therapy

Consultative hematology: hematologic aspects of pregnancy Changing paradigm of early antifungal treatment for hematologic patients in the era of anti-mold prophylaxis

Department of Hemato-Oncology, Internal Medicine Inje University College of MedicineE-mail : [email protected]

Department of Pediatrics Kyung Hee University College of MedicineE-mail : [email protected]

Department of Internal Medicine Chonbuk National University HospitalE-mail : [email protected], [email protected]

Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children’s Research Hospital, USAE-mail : [email protected]

Department of Internal Medicine Gangnam Severance Hospital, Yonsei University College of MedicineE-mail : [email protected]

Department of Internal Medicine II Wuerzburg University Medical Center, Wuerzburg, GermanyE-mail: [email protected]

Won Sik Lee, M.D., Ph.D. Hoi Soo Yoon, M.D., Ph.D.

Ho-Young Yhim, M.D., Ph.D. Wing Leung, M.D., Ph.D.

Yu Ri Kim, M.D., Ph.D. Werner J. Heinz, M.D., Ph.D.

Education Session I Education Session I

Education Session I Plenary Session

Education Session I Luncheon Symposium


5월 29일(금) 13:40 - 15:00 5월 29일(금) 13:40 - 15:00

5월 29일(금) 13:40 - 15:00 5월 29일(금) 13:40 - 15:00

5월 29일(금) 13:40 - 15:00 5월 29일(금) 13:40 - 15:00

NK cells with high anti-tumor activity can be isolated and expanded in a simple and cost-effective mannerStrategies to extend immune cell memory and longevity can be achieved by genetic modificiation, combination therapy and nano-engineeringThese approaches are effective in preclinical in vitro studies and murine models

In this topic, current guidelines and issues on the management of VTE will be presented. The backgrounds to introduce DOAC, the characteristics of different DOAC’s, practical issues in the use of DOAC’s and the management of DOAC associated bleeding complications will be dealt.

Pig islets are an alternative source for islet transplantation to treat type 1 diabetes (T1D), but reproducible curative potential in the pig-to-nonhuman primate (NHP) model has not been demonstrated. Porcine islets were transplanted into diabetic rhesus macaque and ex vivo expanded autologous regulatory T cells were adoptively transferred into the recipient along with anti-CD154 Ab based immunosuppressants. Pig islet grafts survived and maintained normoglycemia for > 6 months in 4 of 5 consecutive immunosuppressed NHPs. Tregs contributed to better graft survival and better glycemic control. The putative underlying mechanisms by which Treg controls immune response will be discussed in this talk.

Unlike warfarin, DOACs exhibit predictable pharmacokinetics and pharmacodynamics. So, it could be administered at fixed doses without routine coagulation monitoring. However, widely used global and special coagulation tests in clinical laboratories are ffected by DOACs. .DOACs are powerful tools for managing hypercoagulable patients, but, their use introduces new challenges in terms of test interpretation and therapeutic monitoring.

In the previous study, we demonstrated that the target protein was mainly involved in the induction of liver T-, NKT-cell tolerance and enhancement of Treg cell differentiation. In the present study, we found that the target protein is expressed on tumor-associated macrophages (TAM) as well as on cancer cells of multiple myeloma. In mouse multiple myeloma model, mice lacking the target gene reduced the tumor growth and showed an increased tumor-specific T cell activity. Blockade of the target with antagonistic antibody reduced the tumor growth and enhanced the survival of tumor-bearing mice. Therefore, targeting a new immune checkpoint could be an effective immunotherapy for multiple myeloma.

New anticoagulants related bleeding management in real world practice.

Role of NK cell in CML therapy Management of VTE in the era of DOAC

Harnessing regulatory T cells for control of immune response in pig to nonhuman primates pancreatic islet transplantation model

DOACs and thrombophilia testing: facts and artifacts

Targeting immune checkpoints can be a new immunotherapy approach for multiple myeloma

Management of major bleeding with the old and new anticoagulants

Department of Biochemistry, Korea University College of MedicineE-mail : [email protected]

Division of Hematology-Oncology Department of Internal Medicine, CHA University E-mail : [email protected]

Department of Microbiology and Immunology, Xenotransplantation Research Center, Seoul National University College of MedicineE-mail : [email protected]

Department of laboratory Medicine University of Ulsan College of Medicine, Asan Medical CenterE-mail : [email protected]

Department of Microbiology and Immunology, Advanced Research Center for Multiple MyelomaInje University College of [email protected]

Department of Internal Medicine, Soonchunhyang University HospitalE-mail : [email protected]

Kyung-Mi Lee, Ph.D. Doyeun Oh, M.D., Ph.D.

Chung-Gyu Park, M.D., Ph.D. Seongsoo Jang, M.D., Ph.D.

Inhak Choi, M.D., Ph.D. Kyoung Ha Kim, M.D.

Scientific Session I Scientific Session II




5월 29일(금) 13:40 - 15:00 5월 30일(토) 09:40 - 11:00

5월 29일(금) 13:40 - 15:00 5월 30일(토) 09:40 - 11:00

5월 29일(금) 13:40 - 15:00 5월 30일(토) 09:40 - 11:00

Acute myeloid leukemia (AML) is mainly a disease of the elderly, and elderly AML is a biologically and clinically distinct disease. Survival for younger patients with AML has improved steadily over 40 years, however, the outcome of elderly AML is still dismal. Unfavorable cytogenetics, antecedent hematologic disorders, expression of multidrug resistance phenotype, comorbidities and diminished functional reserves are associated with poor outcome. In this talk, I will review and discuss how to approach to the elderly patients with AML for the maximal response.

Hemophagocytic lymphohistiocytosis (HLH) is characterized by uncontrolled proliferation of activated T cells and macrophages with overproduction of proinflammatory cytokines. This talk describes characteristics of immunophenotype and cytokine profiles in HLH with particular focus on Epstein-Barr virus-associated HLH that is the most frequent subtype of HLH in Japan and perforin deficiency that represents most common form of familial HLH.

Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia with early catastrophic clinical feature and specific molecular pathogenesis. This type of leukemia is one of the most exciting stories of modern medicine. Progressing in medicine, the majority of patients are now cured with the advent of molecularly targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Although there are excellent outcome to modern therapy, there are still early mortality and therapy related serious complication remained. This talk include recent treatment guideline, risk adapted treatment and supportive management in APL.

‘Immune checkpoint’ mechanisms suppress tumor antigen-specific T cell responses and contribute to T cell exhaustion in patients with cancer. To restore the T cell response in cancer patients, anti-CTLA-4 and anti-PD-1 (or anti-PD-L1) blocking antibodies were recently developed and known as ‘immune checkpoint modulators’. In this lecture, immunological background of CTLA-4 and PD-1 will be reviewed, and the history and future of immune checkpoint modulators will be discussed.

Acute myeloid leukemia (AML) is the second most common form of leukemia after acute lymphoblastic leukemia in children and adolescents, and accounts for approximately 25-30% of pediatric leukemias in Korea. In the past, patients with AML had a uniformly dismal prognosis. However, improvements in risk stratification based on genetic and cytogenetic abnormalities harbored by the leukemic blast, as well as response to therapy, and advances in hematopoietic cell transplantation (HCT) methodology and supportive care have all contributed to better survival for childhood AML. Several national and multi-national trials now report around 60% event-free survival (EFS) and 70% overall survival (OS). Recent discovery of important prognostic markers in AML has confirmed that AML is a heterogeneous disease. Genetic and cytogenetic abnormalities combined with patient response to initial therapy have helped classify patients according to overall prognosis, so that low risk patients may benefit from chemotherapy-based treatment only, while high risk patients may undergo transplant from alternative donors, if necessary. Although the outcome of childhood AML has improved considerably, much of this is a result of better supportive care and advances in HCT methodology. Recent genetic findings of AML have yet to translate into better survival for these patients. Improving the outcome of pediatric AML will require a more precise delineation of risk groups, and the implementation of new therapy and perhaps targeted therapy for those who are unlikely to respond to current treatment methods.

Extranodal NK/T cell lymphoma (ENKL) is strongly associated with Epstein-Barr virus (EBV) infection. This EBV infection is thought to be an early event in the pathogenesis, and additional genetic alterations are essential to induce lymphomagenesis. This talk describes recent genomic studies which can explain molecular pathogenesis of ENKL.

Optimal treatment approaches for elderly AML Immunophenotypic aberrations in hemophagocytic lymphohistiocytosis

Optimal treatment approach for acute promyelocytic leukemia Immunological background of immune checkpoint and its modulation in cancer

Optimal treatment approaches for AML in children, adolescents, and young adults

Lymphoma genesis of NK/T cell lymphoma

Department of Internal Medicine Korea University College of MedicineE-mail : [email protected]

Department of Pediatrics School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University, Kanazawa, JapanE-mail : [email protected]

Division of Hemato-Oncology, Department of Internal Medicine Kosin University Gospel Hospital E-mail : [email protected]

Graduate School of Medical Science and Engineering KAISTE-mail : [email protected]

Department of Pediatrics, Pediatric Hematology-Oncology Seoul St. Mary’s Hospital, The Catholic University of KoreaE-mail : [email protected]

Department of Pathology Samsung Medical Center, Sungkyunkwan University School of MedicineE-mail : [email protected]

Chul Won Choi, M.D., Ph.D. Taizo Wada, M.D., Ph.D.

Yang Soo Kim, M.D., Ph.D. Eui-Cheol Shin, M.D., Ph.D.

Bin Cho, M.D., Ph.D. YoungHyeh Ko, M.D., Ph.D.

Education Session II Scientific Session III

Education Session II Scientific Session III

Education Session II Scientific Session IV


5월 30일(토) 09:40 - 11:00 5월 30일(토) 09:40 - 11:00

5월 30일(토) 09:40 - 11:00 5월 30일(토) 09:40 - 11:00

5월 30일(토) 09:40 - 11:00 5월 30일(토) 09:40 - 11:00

Management of extranodal NK/T-cell lymphoma (ENKL) is changing and evolving. In the previous era, localized and advanced ENKLs were treated with radiotherapy and CHOP, respectively. Throughout clinical trials, it became evident that localized ENKL should be treated with simultaneous chemoradiotherapy with platinum-based regimen, and advanced/relapsed/refractory ENKL with L-asparaginase containing regimens. The present talk focuses on the experience of NK-cell Tumor Study Group including development and expansion of the SMILE regimen.

Fanconi anemia (FA) is the most frequent inherited cause of bone marrow failure. FA is characterized by spontaneous chromosomal breaks and abnormal DNA repair. Major clinical problems include congenital abnormalities, endocrinopathies, early onset bone marrow failure and increased risk of myelodysplastic syndrome, acute leukemia and solid tumors. This talk describes recent insights into FA including the diagnosis, molecular pathway/genetics and treatment.

The issues for the future development of treatment of ENKL are as below. Risk-adapted approach: IPI or Korean prognostic index (KPI) can have prognostic value. However, both models were validated from the cases treated anthracycline based chemotherapy era. New prognostic model should be proposed from the patients treated with new treatments. Role of PET or PET/CT: In general, ENKL is PET-avid. Pet or PET/CT can increase specificity as well as sensitivity. Therefore, inclusion of PET or PET/CT can be recommended for initial staging. Monitoring of circulating EBV DNA : EBV DNA can reflect tumor burden. Therefore, it can be used as useful tumor marker to predict the outcome and follow-up. Salvage regimens after failure of L-asparaginase containing chemotherapy: Based on the experience, gemcitabine seems to be efficient. Gemcitabine based combination chemotherapy regimens can be considered. Targeted agents : Knowledge on the efficacy of novel targeted agents is very scanty. One concern is EBV reactivation after use of HiDAC inhibitor, like romidepsin. Further studies should be done for this area.

Recent advances in the treatment of aplastic anemia made most of patients to expect to improve response and long-term survival. Allogeneic hematopoietic stem cell transplantation (HSCT) of a HLA-matched sibling donor (MSD) is a first-line treatment for newly diagnosed patients with severe aplastic anemia. Immunosuppressive therapy with cyclosporin and/or antithymocyte or antilymphocyte globulin is an alternative to MSD-HSCT and is indicated for patients where no MSD is found. In this topic, current treatment guidline of aplastic anemia and recent trends of allogeneic hematopoietic stem cell transplantation in terms of expanding donor possibility will be addressed.

Telomeres are long hexanucleotide repeats and a protein complex at chromosome ends that are essential for genome integrity. When telomeres become critically short, senescence, apoptosis, or malignant transformation occurs. The telomeropathies are diseases based on the genetics and molecular biology of the telomeres. Aplastic anemias and bone marrow failure recently have been associated with abnormal telomere maintenance. Therefore, identification of short telomeres has potential clinical implications.

Treatment of paroxysmal nocturnal hemoglobinuria (PNH) is mainly supportive. Allogeneic stem cell transplantation is a curative approach; however, it should only be applied to patients with intractable hemolysis or with complications such as secondary bone marrow aplasia or transformation into MDS or AML. Symptomatic hemolytic PNH is now being treated with eculizumab an inhibitor of the terminal complement cascade. Treatment with eculizumab can significantly prevent PNH-related symptoms including the thrombophilia. Nonetheless, a group of patients undergoing eculizumab treatment shows increased erythropoiesis marked by reticulocytosis, various degrees of anemia, and hyperbilirubinemia. This talk describes the current issues in the treatment of PNH.

Current strategy for the management of ENKL Current insights into Fanconi anemia

Future directions of management of ENKL Treatment guidelines of aplastic anemia: current guidelines and expanding donor possibilities

Bone marrow failure and the telomeropathies Current issues in the treatment of paroxysmal nocturnal hemoglobinuria

Department of Oncology and Hematology Shimane University Cancer Center, Izumo, JapanE-mail : [email protected]

Department of Pediatrics Chonnam National University Hwasun Hospital, Chonnam National University Medical School E-mail : [email protected]

Division of Hematology-Oncology Sungkyunkwan UniversityE-mail : [email protected]

Division of Hematology and Oncology, Department of Internal Medicine Ewha Womans University School of MedicineE-mail : [email protected]

Department of Laboratory Medicine University of Ulsan College of Medicine, Asan Medical CenterE-mail : [email protected]

Department of Internal Medicine Chungnam National University School of MedicineE-mail : [email protected]

Ritsuro Suzuki Lee, M.D., Ph.D. Hee Jo Baek, M.D., Ph.D.

Won Seog Kim, M.D., Ph.D. Yeung-Chul Mun, M.D., Ph.D.

Eul-Ju Seo, M.D., Ph.D. Deog-Yeon Jo, M.D., Ph.D.

Scientific Session IV Education Session III

Scientific Session IV Education Session III

Education Session III Education Session III


5월 30일(토) 11:30 - 12:10 5월 30일(토) 13:30 - 15:00

5월 30일(토) 12:10 - 13:30 5월 30일(토) 13:30 - 15:00

5월 30일(토) 13:30 - 15:00 5월 30일(토) 13:30 - 15:00

Myeloproliferative neoplasms (MPN) have heterogeneous clinical features, occasionally similar to those of inflammatory reactions. In 2005 a point mutation (V617F) in the JAK2 gene was described which proved to have a pivotal pathophysiological role in the development of MPN. Since then other mutations in JAK 2 (exon 12) and in JAK2-associated genes MPL and LNK have been described in MPN patients and recently mutations in Calreticulin gene have been found in essential thrombocytosis and myelofibrosis patients. These mutations not only play an important role in confirming the diagnosis, establishing clonality, but are also important prognostic indicators. The advent of powerful sequencing technologies has uncovered further mutations in several genes which will shed further light into the pathophysiology clinical course of MPN and may open novel therapeutic avenues.

The initial treatment strategies for patients with newly diagnosed multiple myeloma (MM) depend upon the patient's, age, ability to undergo stem cell transplantation and risk stratification according to the number of independent molecular cytogenetic markers. The usually recommended approach for the patients with transplantation eligible newly diagnosed MM is bortezomib-based induction chemotherapy followed by autologous stem cell transplantation (ASCT). Three-drug regimens containing bortezomib such as bortezomib-cyclophosphamide-dexamethasone (VCD), bortezomib-thalidomide-dexamethasone (VTD), and bortezomib-lenalidomide-dexamethasone (VRD) are known as highly active induction regimens. In patients with newly diagnosed MM who are not candidates for ASCT due to age or other comorbidities, the major options for initial therapy are the same as those for patients eligible for ASCT. Although the melphalan-based regimens such as VMP (bortezomib-MP) or MPT (MP-thalidomide) have been preferred for transplantation ineligible newly diagnosed MM patients, non melphalan-based regimens such as lenalidomide-dexamethasone (Rd), VCD, and VRD are increasingly used due to concerns about stem cell damage and secondary malignancies such as myelodysplastic syndrome or leukemia.

Over the last decade, a number of new treatments have been approved for the treatment of multiple myeloma. The biggest impact has been on the survival of transplant eligible patients. Data on the best induction therapy combination, the need for stem cell transplantation and post-transplantation therapy will be critically assessed. In addition, the impact of risk-stratification and also minimal residual disease assessment on outcome and choice of therapy will be discussed.

Almost all patients with multiple myeloma who respond initial therapy eventually relapse and need salvage treatment. Although many treatment options are available to the clinicians, it is difficult to choose optimal treatments. Factors used to determine the choice of therapy include a risk stratification, response and tolerability of prior therapies, availability of novel agents, aggressiveness of disease, renal function, and performance status. The optimal treatment of relapsed or refractory multiple myeloma will be discussed in this talk.

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder resulting in monoclonal immunoglobulin production. Because the disease definition is clinicopathological, diagnosis of MM may be difficult. Response to treatment and survival of patients with MM is very heterogeneous, and the variety is related to tumor cell and patient characteristics. This talk describes the revised International Myeloma Working Group (IMWG) criteria for diagnosis of MM and the prognostic factors of MM.

ALL arises from hematopoietic precursors of the lymphoid lineage. With the advances in cytogenetic (and especially molecular) techniques over the last two decades, our understanding of the biology and pathogenesis of leukemia has progressed tremendously. This progression is now in the process of being translated into better biological prognostication, detection of residual disease and tailored/targeted therapy. This talk is focused on recent findings in the cytogenetic and molecular alterations associated with ALL pathogenesis and its prognostic significance.

Impact of recent genetic discoveries on MPN management Recent advances in the treatment of newly diagnosed multiple myeloma

Treatment of transplant eligible myeloma patients An update for the treatment of relapsed or refractory multiple myeloma

Diagnosis and prognostic factors of multiple myeloma Current strategies and refinement of risk classification: focusing on clinical factors

Department of Haematology Instituto Português de Oncologia de Lisboa, Lisbon, PortugalE-mail : [email protected]

Department of Internal Medicine Yonsei University College of Medicine, Severance HospitalE-mail: [email protected]

Division of Clinical Haematology National University Cancer Institute of Singapore, SingaporeE-mail : [email protected]

Hematology-Oncology Clinic National Cancer CenterE-mail : [email protected]

Department of Laboratory Medicine Korea Cancer Center Hospital, Korea Institute of Radiological & Medical SciencesE-mail : [email protected]

Department of Internal Medicine Pusan National University College of Medicine E-mail : [email protected]

Antonio Almeida, M.D., Ph.D. Jin Seok Kim, M.D., Ph.D.

Wee Joo Chng, M.D., Ph.D. HyeonSeok Eom, M.D., Ph.D.

Yoon Hwan Chang, M.D., Ph.D. Ho-Jin Shin, M.D., Ph.D.

Special Lecture Working Party I

Luncheon Symposium Working Party I

Working Party I Working Party II


5월 30일(토) 13:30 - 15:00 5월 30일(토) 13:30 - 15:00

5월 30일(토) 13:30 - 15:00 5월 30일(토) 13:30 - 15:00

5월 30일(토) 13:30 - 15:00 5월 30일(토) 15:20 - 16:50

Over past several decades, numerous cytogenetic and molecular aberrations were discovered and characterized in ALL. The focus of this talk will be the principle genetic abnormalities which are currently used to manage the treatment of patients with ALL as well as newly described aberrations which are likely to impact on clinical care in the near future.

For hemophilia patients, maintenance therapy has become the standard treatment which was recommended by WHO. Under the age of 18years, majority of the severe hemophilia patients are doing maintenance therapy. Hemophilia society needs to extend it to all Korean hemophilia patients.

Minimal residual disease (MRD) is a powerful predictor of the overall response to treatment in childhood acute lymphoblastic leukemia (ALL). MRD may be detected at a sensitivity of at least 10-4 either by molecular means, generally based on polymerase chain reaction (PCR) amplification of rearranged immunoglobulin (Ig) or T-cell receptor genes or by multiparameter flow cytometry. MRD is replacing morphology to measure treatment response in ALL and is being used, with promising results, for risk-stratification in clinical protocols. Recent studies provide further evidence of its prognostic significance and point to possible strategies to increase the reliability, applicability and sensitivity of MRD testing. The combined use of MRD and emerging information on genetic lesions of ALL offers the possibility of further refining risk-assignment approaches.

Hemophilic arthropathy, one of main characteristics to treat in hemophilic patient, is related with acute as well as chronic pain. Comparing to other disease related to chronic pain, such as osteroarthritis or rheumatoid arthritis, management of pain in hemophilia is challenging issues and recently being started to develop appropriated systems and guidelines. Brief reviews of literatures are to be covered also.

With the improvement in the management of hemophilia, the individual approach to comprehensive care for hemophilia patient is now a well-established issue. For patients with severe hemophilia, the optimal regimen for personalized prophylaxis is based on different individual pharmacokinetics (PK) to factor concentrates and bleeding tendency. For patients with inhibitors, individual PK study will be even more helpful assessment of the full tolerance at the end of immune tolerance induction, the method to eradicate inhibitors. Whether factor concentrates or bypassing agents for bleeding control, the monitoring the effectiveness according to doses of agents and factor levels is needed to tailor an individual management. I will talk and discuss these monitoring techniques in hemophilia.

Recently, mutations of many epigenetic regulator genes such as DNMT3A, TET2, IDH1/2, and ASXL were identified and studied as a link between the altered epigenetic signature and somatic gene mutations in AML/MDS. First, this talk will describe the epigenetic regulator genes’ functional and mutational characteristics in AML/MDS. Second, their clinical implications in the pathogenesis and prognosis will be reviewed. And shortly, this talk will present the mutational and functional study data that we currently have.

Approaches to detect new genetic subtypes Optimal maintenance therapy for the management of hemophilia

Recent advances to detect MRD in acute lymphoblastic leukemia

Pain management in bleeding disorders: comparison with other diseases

Advances in monitoring techniques in hemophilia Clinical implications of epigenetic regulator gene mutation in AML/MDS

Department of Laboratory Medicine Keimyung University School of MedicineE-mail : [email protected]

Korea Hemophilia FoundationE-mail : [email protected]

Department of Laboratory Medicine Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaE-mail : [email protected]

Department of Pediatric Hematology-Oncology, Kyungpook National University Children’s HospitalE-mail : [email protected]

Department of Pediatrics Catholic University of Daegu School of MedicineE-mail : [email protected]

Department of Laboratory Medicine Inje University College of MedicineE-mail: [email protected]

Jung Sook Ha, M.D., Ph.D. Kiyoung Yoo, M.D., Ph.D.

Myungshin Kim, M.D., Ph.D. Ji Yoon Kim, M.D., Ph.D.

Eun Jin Choi, M.D., Ph.D. Seung Hwan Oh, M.D.

Working Party II Working Party III

Working Party II Working Party III

Working Party III Working Party IV


5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

Not all patients with higher-risk MDS or AML treated with HMA respond to treatment, and optimization of treatment with HMA needs to be considered. There has been much research into the possibility of improving response rates or the depth and durability of response with HMA, by combining it with other agents such as histone deacetylase (HDAC) inhibitors, lenalidomide, All trans retinoic acid etc. In this topic, I will briefly review encouraging data indicating that the successful future of treatment rests in the combination of multiple treatments modalities to achieve improved clinical outcomes.

In this topic, current status and ongoing research of Korean TTP/HUS as well as update in the management on TTP/HUS will be presented.

Approximately two-thirds of children with acute myeloid leukemia (AML) are cured with intensive multi-agent chemotherapy. However, refractory and relapsed AML remains a significant source of childhood cancer mortality. Identification of specific genetic subgroups within AML and correlation with relapse-free and overall survival rates have allowed risk stratification of many patients and have decreased use of adjuvant hematopoietic stem cell transplantation for favorable risk group patients. Nonetheless, further therapy intensification with traditional cytotoxic chemotherapy in pediatric AML is not feasible given the risks of both short-term and long-term organ dysfunction. Relapsed and chemotherapy-refractory AML is thus an area of unmet clinical need and presents opportunities for the development of novel targeted therapeutic approaches. New treatments for children with AML are clearly indicated to decrease relapse and improve cure rates. Several promising agents are currently in clinical testing or late preclinical development for AML, including monoclonal antibodies against leukemia cell surface proteins, kinase inhibitors, proteasome inhibitors, epigenetic agents, and chimeric antigen receptor engineered T cell immunotherapies.

Pharmacologic thromboprophylaxis is recommended for hospitalized medical patients with risk of thrombosis. Advanced age is a risk factor for venous thromboembolism (VTE) and elderly compose the most of medical in-patients. Ethnic differences in the incidence of VTE in hospitalized medical patients seems to exist between Korean and western people. Therefore, we conducted a prospective observational study to estimate the incidence of asymptomatic VTE in medically-ill hospitalized elderly patients. Today, I’d like to present the results of prospective observational study on incidence of venous thromboembolism in medically-ill hospitalized elderly patients.

Despite significant advances in knowledge and some improvements of treatment outcomes, a substantial number of patients with AML/MDS eventually experience relapse and death even after allogenic stem cell transplantation. Recently, incorporation of targeted therapies, including hypomethylating agents, into peri-allogenic transplant setting attracts attention because it may have the potential to directly or indirectly augment anti-tumor effect of an allograft.

Major orthopedic surgery, including total hip arthroplasty, total knee arthroplasty, and hip fracture surgery, is known to have the highest risk of venous thromboembolism (VTE) among all surgical procedures. Current international guidelines recommend routine perioperative prophylaxis with low-dose unfractionated heparin, low molecular weight heparin, warfarin, new oral anticoagulants, and aspirin for patients undergoing major orthopedic surgery, if bleeding risk is not so high. However, current evidence suggests that Korean patients had lower incidence of postoperative VTE following major orthopedic surgery than Caucasian patients. However, there are limited data regarding patterns and outcomes of perioperative thromboprophylaxis in Korean patients. Therefore, in this talk, we’ll propose the population-based study investigating proportion and their patterns of pharmacologic prophylaxis among patients undergoing major orthopedic surgery using the Health Insurance Review and Assessment Service (HIRA) database. We also investigate the impact of pharmacologic prophylaxis on VTE development and bleeding complications. This study provides basic information to optimize risk-stratified thromboprophylaxis strategies that balance the risk of VTE and bleeding in Korean patients undergoing major orthopedic surgery.

Combination therapy including HMA for high risk MDS/AML Results of Korean TTP/HUS registry

Therapeutic challenges for pediatric relapsed or refractory AML

Results of prospective study for VTE in medically-ill hospitalized elderly patients

Adjunctive targeted therapies combined with reduced intensity conditioning allografts

Study proposal I: pharmacologic prophylaxis and their outcomes in patients undergoing major orthopedic surgery

Department of Internal Medicine Division of Hemato-Oncoloty, Samsung Medical CenterE-mail : [email protected]

Division of Hematology-Oncology Department of Internal Medicine, School of Medicine, CHA University E-mail : [email protected]

Department of Pediatrics, College of Medicine Chung-Ang UniversityE-mail : [email protected]

Department of Internal Medicine Seoul National University Bundang HospitalE-mail : [email protected], [email protected]

Division of Hematology and Medical Oncology, Department of Internal Medicine, Gachon University School of MedicineE-mail : [email protected]


Silvia Park, M.D., Ph.D. Doyeun Oh, M.D., Ph.D.

Hyery Kim, M.D. Jeong-Ok Lee, M.D.Ph.D.

Junshik Hong, M.D. Ho-Young Yhim, M.D., Ph.D

Working Party IV Working Party V



23대한혈액학회 춘계학술대회 | 22

5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

5월 30일(토) 15:20 - 16:50 5월 30일(토) 15:20 - 16:50

Cancer patients have an increased risk of developing venous thromboembolism (VTE). In addition, cancer patients are also at a higher risk of developing recurrent VTE despite standard anticoagulation therapy. Since the report of CLOT study, low molecular weight heparin as been a standard of care for the initial and long-term therapy of patients with cancer-associated VTE. New oral anticoagulants (NOACs), including rivaroxaban, have recently approved for the treatment of VTE. However, limited data exist in the treatment of cancer-associated VTE with NOACs. The Thrombosis Working Party of the Korean Society of Hematology has been conducting a prospective, multicenter, open-label study investigating efficacy and safety of rivaroxaban in patients with cancer-associated VTE (Clinicaltrials.gov #NCT01989845). In this talk, we’ll present the interim results of the study.

Langerhans cell histiocytosis (LCH) encompasses a wide range of clinical presentation and its clinical course varies widely from spontaneous regression to severe disseminated disease with the risk of permanent consequences. Due to the rarity of LCH, collaborative cooperative group trials have contributed to the development of the treatment protocol. In Korea, Histiocytosis Working Party has reported the outcome of a large, retrospective multicenter study in Korean children with LCH. To overcome the limitation of the retrospective study and better understand its pathobiology and clinical course, a nationwide, multicenter, prospective registry of LCH has been launched in 2013 with the support of Korean Centers for Disease Control. This talk will deal with the current status and future perspectives in a multi-center registry of LCH in Korea.

L-asparaginase is one of the important drugs for treatment of lymphoid malignancies. Thrombotic complications in patients using L-asparaginase mostly affect vein, and arterial thrombosis is rarely reported. Meta-analysis of prospective trials including L-asparaginase as a chemotherapy regimen in acute lymphoblastic leukemias reported thrombotic complications occurring 4.2% and 5.9% in children and adult patients, respectively. There are several studies in Korea reporting thrombosis as a side effect of particular chemotherapeutic regimens, but there is no report analyzing the incidence of thrombosis after L-asparaginase use in large population in Korea. This study aims to investigate the incidence of thrombosis in patients treated with L-asparaginase in Korean population using HIRA (Health Insurance Review and Assessment Service) database, and to analyze factors affecting thrombosis.

Recent advances in the genomic analysis of LCH revealed that LCH is a disease characterized by genetically driven dysregulation of MAP kinase pathway. Immunohistochemical analysis of LCH cells demonstrated phosphorylated MEK and ERK in nearly all LCH patients’ samples, and genomic analysis revealed the presence of BRAF or ARAF mutations in 50-60% cases. These observations suggest that LCH patients are likely to benefit from BRAF inhibitors as in melanoma, and clinical studies are going on.

We will analyze bleeding episodes of our cohort of patients with cancer associated thrombosis (CAT). Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease of severe uncontrolled hyperinflammation caused by persistent stimulation of lymphocytes and histiocytes resulted in hypercytokinemia. This talk describes the recent advances in the treatment of HLH.

Interim report about the efficacy and safety of rivaroxaban in patients with cancer-associated VTE

Current status of a nationwide, multicenter, prospective registry of LCH in Korea

Incidence of thrombosis after L-asparaginase in Korean patients

Genomics of LCH and its clinical implications

Study proposal II: characteristics of bleeding complication in cancer associated VTE

Recent advances in the treatment of HLH


Division of Pediatric Hematology/Oncology, Department of PediatricsAsan Medical Center Children’s Hospital, University of Ulsan College of MedicineE-mail : [email protected]

Department of Internal medicine Dong-A University College of MedicineE-mail : [email protected]

Department of Pediatrics, Division of Hematology-Oncology University of Ulsan College of Medicine & Asan Medical CenterE-mail : [email protected]

Department of Internal Medicine, Soonchunhyang University HospitalE-mail : [email protected]

Department of Pediatrics College of Medicine, Yeungnam University E-mail : [email protected]

Ho-Young Yhim, M.D., Ph.D Kyung-Nam Koh, M.D., Ph.D.

Ji Hyun Lee, M.D., Ph.D. Jong Jin Seo, M.D., Ph.D.

Kyoung Ha Kim, M.D. Jae Min Lee, M.D., Ph.D.

Working Party V Working Party VI



25


The Korean Society of Hematology Scientific Committee

위원장 이제환 울산의대 서울아산병원 내과

간 사 장성수 울산의대 서울아산병원 진단검사의학과

위 원 강형진 서울의대 서울대학교병원 소아청소년과

고경남 울산의대 서울아산병원 소아청소년과

김대영 울산의대 서울아산병원 내과

김명신 가톨릭의대 서울성모병원 진단검사의학과

김미영 한림의대 성심병원 진단검사의학과

김유진 가톨릭의대 서울성모병원 내과

김지명 충남의대 충남대학교병원 진단검사의학과

유건희 성균관의대 삼성서울병원 소아청소년과

임호영 전북의대 전북대학교병원 내과

정낙균 가톨릭의대 서울성모병원 소아청소년과

최철원 고려의대 구로병원 내과

Position Name Affiliation

5월 30일(토) 15:20 - 16:50

Macrophage activation syndrome (MAS) is an overwhelming inflammatory episode which is characterized by activation and expansion of T cells and macrophages. It occurs mostly in patients with various autoimmune diseases. The usual clinical findings include cytopenia, hepatic dysfunction with coagulopathy and increased serum ferritin. MAS share a large portion of clinical manifestation with hereditary hemophagocytic lymphohistiocytosis (HLH) and therefore it is frequently termed as secondary HLH for medical diagnosis. Central pathogenesis is a cytokine storm involving various pro-inflammatory cytokines such as IL-1, IL-6, IL-18, TNFα and IFNγ. The mainstay of treatment is still glucocorticoids and immune-suppressive agents including cyclosporine and cytotoxic agents for patients who fail to respond. Treatment targeting specific cytokine is an clinical trials and the results are confined to only few case reports yet. This talk will focus on new pathogenesis of MAS discovered recently.

Clinical spectrum and treatment of macrophage activation syndromeDepartment of Internal Medicine, Yonsei University College of MedicineE-mail : [email protected]

Soo Jeong Kim, M.D.

Working Party VI


제56차 대한혈액학회 춘계학술대회


Grand Hilton Convention Hall Information

Emerald Hall, Diamond Hall 3F

Convertion Hall 4F

MEMO


서울시 종로구 사직로 8길 오피스텔 220호 (내수동, 경희궁의 아침 2단지)

Tel : 02-516-6581 Fax : 02-516-6582

Documents

2015 제56차 대한혈액학회 춘계학술대회 · 2015. 10. 2. · 3 The 56th Spring Meeting of the Korean Society of Hematology 존경하는 대한혈액학회 회원 여러분!